Oncology CRO Oncotherapeutics Presents at ASH 2011 Annual Meeting

FOR IMMEDIATE RELEASE
Los Angeles, California, United States of America (Free-Press-Release.com) November 23, 2011 -- Oncotherapeutics, an oncology specific Contract Research Organization (CRO) specializing in the oversight and management of clinical trials for cancer, will present final results from a multicenter clinical trial at the American Society of Hematology Annual Meeting in San Diego, California on December 10-13 , 2011.

The title of the poster is:

Bendamustine Combined with Bortezomib has Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study.

With expertise in phase I-IV clinical trials and pharmacokinetic studies, Oncotherapeutics offers a wide array of services that are custom tailored to meet the needs of pharmaceutical and biotech sponsors. Oncotherapeutics is currently recruiting for the following studies:

 A Phase I/II Study of Carfilzomib as a Replacement for Bortezomib for Multiple Myeloma Patients Failing Bortezomib-Containing Regimens

 A Phase III Study of Armodafinil for the Treatment of Cancer-Related Fatigue for Patients with Multiple Myeloma.

For more information on these trials, please visit www.clinicaltrials.gov.

Oncotherapeutics is headquartered in Los Angeles, California. To learn more, please visit www.oncotherapeutics.com . For further information about conducting trials with Oncotherapeutics, please contact Cheryl Cross, Sr. Director New Business Development, at ccross@oncotherapeutics.com.

Bendamustine     Bortizomib     James R. Berenson     md     multiple myeloma     Oncotherapeutics